Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The EASEMENT study: A multicentre, observational, cross-sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable-containing or fully oral therapies.
Ayto R, Annibali O, Biedermann P, Roset M, Sánchez E, Kotb R. Ayto R, et al. Among authors: kotb r. Eur J Haematol. 2024 Jun;112(6):889-899. doi: 10.1111/ejh.14180. Epub 2024 Feb 23. Eur J Haematol. 2024. PMID: 38389468
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database.
Kaedbey R, Reece D, Venner CP, McCurdy A, Su J, Chu M, Louzada M, Jimenez-Zepeda VH, Mian H, Song K, Sebag M, Stakiw J, White D, Reiman A, Aslam M, Kotb R, Bergstrom D, Gul E, LeBlanc R. Kaedbey R, et al. Among authors: kotb r. EJHaem. 2024 Apr 29;5(3):474-484. doi: 10.1002/jha2.894. eCollection 2024 Jun. EJHaem. 2024. PMID: 38895063 Free PMC article.
First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium.
Khan S, Bergstrom DJ, Côté J, Kotb R, LeBlanc R, Louzada ML, Mian HS, Othman I, Colasurdo G, Visram A. Khan S, et al. Among authors: kotb r. Clin Lymphoma Myeloma Leuk. 2024 Oct 23:S2152-2650(24)02385-1. doi: 10.1016/j.clml.2024.10.012. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39567294 Free article. Review.
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner CP, White D, Chu MP, Jimenez-Zepada VH, Song K, Mccurdy A, Mian H, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Kaedbey R, Louzada M, LeBlanc R. Tanguay M, et al. Among authors: kotb r. Cancer Med. 2024 Nov;13(21):e70332. doi: 10.1002/cam4.70332. Cancer Med. 2024. PMID: 39499045 Free PMC article.
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.
McCurdy A, Reece D, Louzada ML, White D, Parkin S, Chu MP, Kotb R, Mian H, Othman I, Su J, Khan A, Gul E, Trudel S. McCurdy A, et al. Among authors: kotb r. Blood Cancer J. 2024 Sep 11;14(1):155. doi: 10.1038/s41408-024-01135-2. Blood Cancer J. 2024. PMID: 39261451 Free PMC article. Clinical Trial.
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.
Venner CP, Duggan P, Song K, Reece D, Sharma S, Su J, Jimenez-Zepeda VH, McCurdy A, Louzada M, Mian H, Sebag M, White D, Stakiw J, Kotb R, Aslam M, Reiman A, Gul E, Chu MP, Bergstrom D, LeBlanc R. Venner CP, et al. Among authors: kotb r. Transplant Cell Ther. 2024 Sep;30(9):889-901. doi: 10.1016/j.jtct.2024.06.030. Epub 2024 Jul 4. Transplant Cell Ther. 2024. PMID: 38971462
80 results